Kling Biotherapeutics – Amsterdam Academic Ventures

Our portfolio

Kling Biotherapeutics

Discovering antibody-based therapeutics, Kling Biotherapeutics targets cancer and infectious diseases. Their platform leverages patient immune repertoires to identify novel therapeutic targets. Kling Biotherapeutics has a rich pipeline of antibodies for oncology and infectious disease applications in clinical and preclinical development.

Industry: Infectious Disease, Oncology, Therapeutics

Want to get in contact about Kling Biotherapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Improving orthopedic diagnostics with advanced joint loading and imaging technology.

Combining quantum computing and classical simulations for material science.

A citizen engagement platform for real-time polling and response aggregation.

Developing bispecific antibodies to enhance cancer immunotherapy.

Improving orthopedic diagnostics with advanced joint loading and imaging technology.

Combining quantum computing and classical simulations for material science.

A citizen engagement platform for real-time polling and response aggregation.

Developing bispecific antibodies to enhance cancer immunotherapy.